Daxor Corp Announces Q2 2005 Earnings
6th Sep 2005, 21:42 GMT
Daxor Corp: 3 Months Ended 6 Months Ended 6/30/2005 6/30/2005 2005 2004 2005 2004 ---- ---- ---- Total Operating Revenues $ 270,659 $ 210,165 $ 556,572 $ 500,089 Total Costs & Expenses $ 1,492,405 $1,166,366 $ 3,003,829 $2,241,884 Total Other Income $ 129,680 $ 650,170 $ 1,004,482 $1,337,204 Net Loss $ $ $ $ Weighted Average Number of Shares Outstanding 4,637,326 4,611,993 4,632,493 4,622,326 Equivalent Share $ $ $ $ Daxor Corp, a medical instrumentation and biotech company, announced Q2 earnings for 2005.
Latest news from Bio-Technology News from myHealthcareNews.com:
- IBT Labs Invests $2 mln to Expand Pharmaceutical Services Division
- Mercury Computer Systems Collaborates with Boston Univ to Deliver Biotech Application on the Cell BE Processor
- Nabi Biopharmaceuticals and 3rd Point Reach Agreement
- Epratuzumab and Rituximab Have Different Modes of Action
- avVaa World Health Care Products Signs New Spokesman
- China Biopharma Delivers 1.5 mln Doses of Flu Vaccine in China
- Osteologix Appoints Jeremy Curnock Cook to its Board
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
- Medarex to Receive Milestone Payment from Amgen
- Arqule Early Cancer Study Shows Progress